Current understanding and controversies on the clinical implications of fibroblast growth factor 21.

Crit Rev Clin Lab Sci

Division of Advanced Diagnostics, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.

Published: August 2021

Metabolic functions of the hepatic hormone fibroblast growth factor 21 (FGF21) have been recognized for more than a decade in studying the responses of human subjects and rodent models to nutritional stresses such as fasting, high-fat diet or ketogenic diet consumption, and ethanol intake. Our interest in the beneficial metabolic effects of FGF21 has risen due to its potential ability to serve as a therapeutic agent for various metabolic disorders, including type 2 diabetes, obesity, and fatty liver diseases, as well as its potential to act as a diagnostic or prognostic biomarker for metabolic and other disorders. Here, we briefly review the FGF21 gene and protein structures, its expression pattern, and cellular signaling cascades that mediate FGF21 production and function. We mainly focus on discussing experimental and clinical literature pertaining to FGF21 as a therapeutic agent. Furthermore, we present several lines of investigation, including a few studies conducted by our team, suggesting that FGF21 expression and function can be regulated by dietary polyphenol interventions. Finally, we discuss the literature debating FGF21 as a potential biomarker in various disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10408363.2020.1864278DOI Listing

Publication Analysis

Top Keywords

fibroblast growth
8
growth factor
8
therapeutic agent
8
metabolic disorders
8
fgf21
7
current understanding
4
understanding controversies
4
controversies clinical
4
clinical implications
4
implications fibroblast
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!